Seeking Alpha

Jazz Pharmaceuticals (JAZZ) is down 2.1% premarket, adding to the losses seen yesterday due to...

Jazz Pharmaceuticals (JAZZ) is down 2.1% premarket, adding to the losses seen yesterday due to an FDA warning letter related to its Xyrem drug. However, Jefferies and Piper have come to Jazz's defense, with each noting that the warning merely involves the company's monitoring procedures, rather than any production issues.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector